Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans.

As part of a Phase I clinical trial, 5 patients received 5-fluorouracil (FU) both singly and in combination with misonidazole (MISO) for the treatment of gastrointestinal cancer. Concentrations of total FU and F-containing metabolites in urine specimens, taken during 48 h after therapy, were determi...

Descripción completa

Detalles Bibliográficos
Autores principales: McDermott, B. J., Van den Berg, H. W., Martin, W. M., Murphy, R. F.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1983
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011515/
https://www.ncbi.nlm.nih.gov/pubmed/6639859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011515/
https://www.ncbi.nlm.nih.gov/pubmed/6639859

Ejemplares similares